TRAVOPROST

Post-LOE

travoprost ophthalmic solution usp, 0.004%

Alembic

ANDAOPHTHALMICSOLUTION/DROPS

Approved

Dec 2019

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

3/8 — Basic

Drug data last refreshed 14h ago

$0.0BPart D

Mechanism of Action

Pharmacologic Class:

Prostaglandin Analog

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (20)

NCT07495852Phase 3Recruiting

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Started Feb 2026

510 enrolled

Glaucoma

NCT07400926N/ARecruiting

Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

Started Dec 2025

30 enrolled

Open Angle Glaucoma (OAG)Ocular Hypertension (OH)

NCT07075718Phase 2/3Recruiting

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Started Jun 2025

610 enrolled

Glaucoma

NCT06152861Phase 2Unknown

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

Started Nov 2023

250 enrolled

Open Angle GlaucomaOcular Hypertension

NCT06066645Phase 4Recruiting

Travoprost Intraocular Implant + iStent Infinite

Started Sep 2023

150 enrolled

Glaucoma, Open-Angle

Worked on TRAVOPROST at Alembic? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.